Haemonetics (HAE) Tops Q4 EPS by 6c, Offers FY Guidance

Haemonetics (NYSE: HAE) reported Q4 EPS of $0.65, $0.06 better than the analyst estimate of $0.59. Revenue for the quarter came in at $265 million versus the consensus estimate of $257.82 million.

GUIDANCE:

Haemonetics sees FY2023 EPS of $2.50-$2.90, versus the consensus of $2.53.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance